Picture of Conmed logo

CNMD Conmed News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareBalancedMid CapNeutral

Conmed Corp expected to post earnings of 91 cents a share - Earnings Preview

* Conmed Corp  CNMD.N   CNMD.K  is expected to show a rise
in
quarterly revenue when it reports  results on July 31 for the
period ending June 30 2024
    * The Largo Florida-based  company is expected to report a
4.6% increase in revenue to $332.325 million from $317.65
million a year ago, according to the mean estimate from 8
analysts, based on LSEG data.
    * ​LSEG's mean analyst estimate for Conmed Corp is for
earnings of
91 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," 3
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Conmed Corp
is
$88.00​, above​ its last closing price of $70.08. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Mar. 31 2024  0.74        0.74       0.79      Beat    7
 Dec. 31 2024  1.11        1.11       1.06      Missed  -4.5
 Sep. 30 2023  0.83        0.83       0.90      Beat    8.4​
 Jun. 30 2023  0.79        0.79       0.83      Beat    4.5
 ​​Mar.        0.60        0.60       0.66      Beat    10.3
 31 2023                                                
 Dec. 31 2022  0.89        0.90       0.42      Missed  -53.5​
 Sep. 30 2022  0.75        0.75       0.77      Beat    2.4
 Jun. 30 2022  0.74        0.75       0.76      Beat    1.8
 This summary was machine generated July 29 at 20:56 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)

Recent news on Conmed

See all news